Assertio Therapeutics, Inc. buy melinda
Start price
10.03.17
/
50%
€14.07
Target price
11.09.17
€18.94
Performance (%)
-60.77%
End price
11.09.17
€5.52
Summary
This prediction ended on 11.09.17 with a price of €5.52. The BUY prediction by melinda for Assertio Therapeutics, Inc. performed very badly with a performance of -60.77%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Assertio Therapeutics, Inc. | -2.667% | -2.667% | -87.813% | -92.074% |
| iShares Core DAX® | 0.754% | -1.027% | 14.485% | 59.395% |
| iShares Nasdaq 100 | -2.859% | -4.266% | 2.185% | 85.679% |
| iShares Nikkei 225® | 4.946% | 5.736% | 25.355% | 57.349% |
| iShares S&P 500 | -1.254% | -2.357% | 1.146% | 58.964% |
Comments by melinda for this prediction
In the thread Assertio Therapeutics, Inc. diskutieren
Arzneimittel
Depomed, Inc. ist ein pharmazeutisches Unternehmen , das produziert und vertreibt pharmazeutische Produkte Schmerzen und andere zentrale Nervensystem conditions.Its Marken gehören Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER und Unternehmen zu behandeln NUCYNTA.The wurde 1995 von John W. Shell 7. August gegründet
(Laufzeit überschritten)
Stopped prediction by melinda for Assertio Therapeutics, Inc.
Assertio Therapeutics, Inc.
Start price
Target price
Perf. (%)
€1.08
14.12.19
14.12.19
€2.00
22.05.20
22.05.20
-32.41%
22.05.20
22.05.20
Assertio Therapeutics, Inc.
Start price
Target price
Perf. (%)
€3.06
26.05.19
26.05.19
€4.06
30.10.19
30.10.19
-71.43%
30.10.19
30.10.19
Assertio Therapeutics, Inc.
Start price
Target price
Perf. (%)
€7.64
13.12.17
13.12.17
€9.92
13.06.18
13.06.18
-18.18%
13.06.18
13.06.18
Assertio Therapeutics, Inc.
Start price
Target price
Perf. (%)
€8.47
13.12.17
13.12.17
€11.00
13.06.18
13.06.18
-18.18%
13.06.18
13.06.18
Assertio Therapeutics, Inc.
Start price
Target price
Perf. (%)
€4.51
24.05.13
24.05.13
€6.00
25.11.13
25.11.13
32.25%
25.11.13
25.11.13